Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2005

Open Access 01-12-2005 | Research

Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?

Authors: A Simon Pickard, Zhixiao Wang, Surrey M Walton, Todd A Lee

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Login to get access

Abstract

Background

Cost utility analysis (CUA) using SF-36/SF-12 data has been facilitated by the development of several preference-based algorithms. The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and provide some guidance on selecting an appropriate algorithm.

Methods

Two sets of data were used: (1) a clinical trial of adult asthma patients; and (2) a longitudinal study of post-stroke patients. Incremental costs were assumed to be $2000 per year over standard treatment, and QALY gains realized over a 1-year period. Ten published algorithms were identified, denoted by first author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback, Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incremental cost-utility ratios (ICURs) for each algorithm, stated in dollars per quality-adjusted life year ($/QALY), were ranked and compared between datasets.

Results

In the asthma patients, estimated ICURs ranged from Lawrence's SF-12 algorithm at $30,769/QALY (95% CI: 26,316 to 36,697) to Brazier's SF-36 algorithm at $63,492/QALY (95% CI: 48,780 to 83,333). ICURs for the stroke cohort varied slightly more dramatically. The MEPS-based algorithm by Franks et al. provided the lowest ICUR at $27,972/QALY (95% CI: 20,942 to 41,667). The Fryback and Shmueli algorithms provided ICURs that were greater than $50,000/QALY and did not have confidence intervals that overlapped with most of the other algorithms. The ICUR-based ranking of algorithms was strongly correlated between the asthma and stroke datasets (r = 0.60).

Conclusion

SF-36/SF-12 preference-based algorithms produced a wide range of ICURs that could potentially lead to different reimbursement decisions. Brazier's SF-36 and SF-12 algorithms have a strong methodological and theoretical basis and tended to generate relatively higher ICUR estimates, considerations that support a preference for these algorithms over the alternatives. The "second-generation" algorithms developed from scores mapped from other indirect preference-based measures tended to generate lower ICURs that would promote greater adoption of new technology. There remains a need for an SF-36/SF-12 preference-based algorithm based on the US general population that has strong theoretical and methodological foundations.
Literature
1.
go back to reference Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. 2nd edition. Oxford, NY, Oxford University Press; 1997. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. 2nd edition. Oxford, NY, Oxford University Press; 1997.
2.
go back to reference Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press; 1996. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press; 1996.
3.
4.
go back to reference Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002, 40: 113–128. 10.1097/00005650-200202000-00006PubMedCrossRef Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002, 40: 113–128. 10.1097/00005650-200202000-00006PubMedCrossRef
5.
go back to reference Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q: Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996, 34: 702–722. 10.1097/00005650-199607000-00004PubMedCrossRef Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q: Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996, 34: 702–722. 10.1097/00005650-199607000-00004PubMedCrossRef
6.
go back to reference Brooks R: EuroQol: the current state of play. Health Policy 1996, 37: 53–72. 10.1016/0168-8510(96)00822-6PubMedCrossRef Brooks R: EuroQol: the current state of play. Health Policy 1996, 37: 53–72. 10.1016/0168-8510(96)00822-6PubMedCrossRef
7.
go back to reference Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef
8.
go back to reference Ware JEJ, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI, Quality Metric Incorporated; 1993. Ware JEJ, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI, Quality Metric Incorporated; 1993.
9.
go back to reference Ware JE, Kosinski M, Keller SD: SF-12: How to scores the SF-12 Physical and Mental Health Summary Scales. Lincoln, RI, QualityMetric Inc.; 1998. Ware JE, Kosinski M, Keller SD: SF-12: How to scores the SF-12 Physical and Mental Health Summary Scales. Lincoln, RI, QualityMetric Inc.; 1998.
10.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8PubMedCrossRef Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8PubMedCrossRef
11.
go back to reference Franks P, Lubetkin EI, Gold MR, Tancredi DJ: Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Med Care 2003, 41: 1277–1283. 10.1097/01.MLR.0000093480.58308.D8PubMedCrossRef Franks P, Lubetkin EI, Gold MR, Tancredi DJ: Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Med Care 2003, 41: 1277–1283. 10.1097/01.MLR.0000093480.58308.D8PubMedCrossRef
12.
go back to reference Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE: Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997, 17: 1–9.PubMedCrossRef Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE: Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997, 17: 1–9.PubMedCrossRef
13.
go back to reference Lawrence WF, Fleishman JA: Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making 2004, 24: 160–169. 10.1177/0272989X04264015PubMedCrossRef Lawrence WF, Fleishman JA: Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making 2004, 24: 160–169. 10.1177/0272989X04264015PubMedCrossRef
14.
go back to reference Lundberg L, Johannesson M, Isacson DG, Borgquist L: The relationship between health-state utilities and the SF-12 in a general population. Med Decis Making 1999, 19: 128–140.PubMedCrossRef Lundberg L, Johannesson M, Isacson DG, Borgquist L: The relationship between health-state utilities and the SF-12 in a general population. Med Decis Making 1999, 19: 128–140.PubMedCrossRef
15.
go back to reference Nichol MB, Sengupta N, Globe DR: Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001, 21: 105–112. 10.1177/02729890122062352PubMedCrossRef Nichol MB, Sengupta N, Globe DR: Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001, 21: 105–112. 10.1177/02729890122062352PubMedCrossRef
16.
go back to reference Shmueli A: The relationship between the visual analog scale and the SF-36 scales in the general population: an update. Med Decis Making 2004, 24: 61–63. 10.1177/0272989X03261562PubMedCrossRef Shmueli A: The relationship between the visual analog scale and the SF-36 scales in the general population: an update. Med Decis Making 2004, 24: 61–63. 10.1177/0272989X03261562PubMedCrossRef
17.
go back to reference Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef
18.
go back to reference Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H: Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making 2004, 24: 247–254. 10.1177/0272989X04265477PubMedCrossRef Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H: Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making 2004, 24: 247–254. 10.1177/0272989X04265477PubMedCrossRef
19.
go back to reference Lee TA, Hollingworth W, Sullivan SD: Comparison of directly elicited preferences to preferences derived from the SF-36 in adults with asthma. Med Decis Making 2003, 23: 323–334. 10.1177/0272989X03256009PubMedCrossRef Lee TA, Hollingworth W, Sullivan SD: Comparison of directly elicited preferences to preferences derived from the SF-36 in adults with asthma. Med Decis Making 2003, 23: 323–334. 10.1177/0272989X03256009PubMedCrossRef
20.
go back to reference Lobo FS, Gross CR, Matthees BJ: Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Qual Life Res 2004, 13: 377–388. 10.1023/B:QURE.0000018488.95206.d6PubMedCrossRef Lobo FS, Gross CR, Matthees BJ: Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Qual Life Res 2004, 13: 377–388. 10.1023/B:QURE.0000018488.95206.d6PubMedCrossRef
21.
go back to reference Lenert LA, Sherbourne CD, Sugar C, Wells KB: Estimation of utilities for the effects of depression from the SF-12. Med Care 2000, 38: 763–770. 10.1097/00005650-200007000-00008PubMedCrossRef Lenert LA, Sherbourne CD, Sugar C, Wells KB: Estimation of utilities for the effects of depression from the SF-12. Med Care 2000, 38: 763–770. 10.1097/00005650-200007000-00008PubMedCrossRef
22.
go back to reference Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG: The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ 2002, 11: 71–85. 10.1002/hec.650PubMedCrossRef Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG: The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ 2002, 11: 71–85. 10.1002/hec.650PubMedCrossRef
23.
go back to reference Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31: 1–11. 10.1097/00003246-200301000-00001PubMedCrossRef Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31: 1–11. 10.1097/00003246-200301000-00001PubMedCrossRef
24.
go back to reference Keeler EB, Robalino DA, Frank JC, Hirsch SH, Maly RC, Reuben DB: Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care 1999, 37: 1199–1206. 10.1097/00005650-199912000-00003PubMedCrossRef Keeler EB, Robalino DA, Frank JC, Hirsch SH, Maly RC, Reuben DB: Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care 1999, 37: 1199–1206. 10.1097/00005650-199912000-00003PubMedCrossRef
25.
go back to reference Wu SY, Sainfort F, Tomar RH, Tollios JL, Fryback DG, Klein R, Klein BEK: Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care 1998, 21: 725–731.PubMedCrossRef Wu SY, Sainfort F, Tomar RH, Tollios JL, Fryback DG, Klein R, Klein BEK: Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care 1998, 21: 725–731.PubMedCrossRef
26.
go back to reference Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA: Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001, 56: 779–784. 10.1136/thorax.56.10.779PubMedCentralPubMedCrossRef Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA: Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001, 56: 779–784. 10.1136/thorax.56.10.779PubMedCentralPubMedCrossRef
27.
go back to reference Gray A, McNamara I, Aziz T, Gregory A, Bain P, Wilson J, Scott R: Quality of life outcomes following surgical treatment of Parkinson's disease. Movement Disorders 2002, 17: 68–75. 10.1002/mds.1259PubMedCrossRef Gray A, McNamara I, Aziz T, Gregory A, Bain P, Wilson J, Scott R: Quality of life outcomes following surgical treatment of Parkinson's disease. Movement Disorders 2002, 17: 68–75. 10.1002/mds.1259PubMedCrossRef
28.
go back to reference Pickard AS, Johnson JA, Feeny DH, Carriere KC, Shuaib A, Nasser AM: Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. Stroke 2004, 35: 607–612. 10.1161/01.STR.0000110984.91157.BDPubMedCrossRef Pickard AS, Johnson JA, Feeny DH, Carriere KC, Shuaib A, Nasser AM: Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. Stroke 2004, 35: 607–612. 10.1161/01.STR.0000110984.91157.BDPubMedCrossRef
29.
go back to reference Bardage C, Isacson D, Ring L, Bingefors K: A Swedish population-based study on the relationship between the SF-36 and health utilities to measure health in hypertension. Blood Press 2003, 12: 203–210. 10.1080/08037050310002083PubMedCrossRef Bardage C, Isacson D, Ring L, Bingefors K: A Swedish population-based study on the relationship between the SF-36 and health utilities to measure health in hypertension. Blood Press 2003, 12: 203–210. 10.1080/08037050310002083PubMedCrossRef
30.
go back to reference Gabriel SE, Kneeland TS, Melton LJ, Moncur MM, Ettinger B, Tosteson AN: Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999, 19: 141–148.PubMedCrossRef Gabriel SE, Kneeland TS, Melton LJ, Moncur MM, Ettinger B, Tosteson AN: Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999, 19: 141–148.PubMedCrossRef
31.
go back to reference National Institute for Clinical Excellence. Health Select Committee Inquiry: submission of supplementary evidence. Paper 2 of 2. http://www.niceorguk/pageaspx?o=27652 [accessed June 10, 2004] 2002. National Institute for Clinical Excellence. Health Select Committee Inquiry: submission of supplementary evidence. Paper 2 of 2. http://www.niceorguk/pageaspx?o=27652 [accessed June 10, 2004] 2002.
32.
go back to reference National Institute for Clinical Excellence. NICE Guidance on the use of orlistat for the treatment of obesity in adults. Technology Appraisal Guidance. http://www.niceorguk/pageaspx?o=15712 [accessed June 10, 2004] 2002. National Institute for Clinical Excellence. NICE Guidance on the use of orlistat for the treatment of obesity in adults. Technology Appraisal Guidance. http://www.niceorguk/pageaspx?o=15712 [accessed June 10, 2004] 2002.
33.
go back to reference Towse A: What is NICE's threshold? An external view. In Devlin N, Towse A. (eds) Cost effectiveness thresholds: economic and ethical issues. King's Fund /Office of Health Economics: London. 2002. Towse A: What is NICE's threshold? An external view. In Devlin N, Towse A. (eds) Cost effectiveness thresholds: economic and ethical issues. King's Fund /Office of Health Economics: London. 2002.
34.
go back to reference Devlin N, Parkin D: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13: 437–452. 10.1002/hec.864PubMedCrossRef Devlin N, Parkin D: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13: 437–452. 10.1002/hec.864PubMedCrossRef
35.
go back to reference Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Cmaj 1992, 146: 473–481.PubMedCentralPubMed Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Cmaj 1992, 146: 473–481.PubMedCentralPubMed
36.
go back to reference Salzmann P, Kerlikowske K, Phillips K: Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997, 127: 955–965.PubMedCrossRef Salzmann P, Kerlikowske K, Phillips K: Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997, 127: 955–965.PubMedCrossRef
37.
go back to reference Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM: Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997, 126: 337–346.PubMedCrossRef Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM: Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997, 126: 337–346.PubMedCrossRef
38.
go back to reference Pickard AS, Johnson JA, Feeny DH: Responsiveness of the SF-36, HUI, and EQ-5D in stroke. Qual Life Res 2005, 14: 207–219. 10.1007/s11136-004-3928-3PubMedCrossRef Pickard AS, Johnson JA, Feeny DH: Responsiveness of the SF-36, HUI, and EQ-5D in stroke. Qual Life Res 2005, 14: 207–219. 10.1007/s11136-004-3928-3PubMedCrossRef
39.
go back to reference Brazier J, Deverill M, Green C: A review of the use of health status measures in economic evaluation. J Health Serv Res Policy 1999, 4: 174–184.PubMed Brazier J, Deverill M, Green C: A review of the use of health status measures in economic evaluation. J Health Serv Res Policy 1999, 4: 174–184.PubMed
40.
go back to reference Torrance GW, Feeny D, Furlong W: Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001, 21: 329–334. 10.1177/02729890122062622PubMedCrossRef Torrance GW, Feeny D, Furlong W: Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001, 21: 329–334. 10.1177/02729890122062622PubMedCrossRef
41.
go back to reference Johnson JA, Ohinmaa A, Murti B, Sintonen H, Coons SJ: Comparison of Finnish and U.S.-based visual analog scale valuations of the EQ-5D measure. Med Decis Making 2000, 20: 281–289.PubMedCrossRef Johnson JA, Ohinmaa A, Murti B, Sintonen H, Coons SJ: Comparison of Finnish and U.S.-based visual analog scale valuations of the EQ-5D measure. Med Decis Making 2000, 20: 281–289.PubMedCrossRef
42.
go back to reference Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13: 873–884. 10.1002/hec.866PubMedCrossRef Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13: 873–884. 10.1002/hec.866PubMedCrossRef
Metadata
Title
Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
Authors
A Simon Pickard
Zhixiao Wang
Surrey M Walton
Todd A Lee
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-3-11

Other articles of this Issue 1/2005

Health and Quality of Life Outcomes 1/2005 Go to the issue